GSK Licenses Lexicon s Gene Targeting Technologies | GenomeWeb

NEW YORK, Aug 15 - GlaxoSmithKline has agreed to a multi-year, non-exclusive sublicense to Lexicon Genetic’s gene targeting technologies, Lexicon said Wednesday.

The deal brings the total number of licensees for the technologies to 15.

Under the terms of the agreement, GlaxoSmithKline will pay a one-time fee of an undisclosed amount.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.